The invention relates to the technical field of
biology, in particular to a nano-
antibody GN1 specifically combined with a GPC3
protein. The nano-
antibody GN1 is composed of a variable region of a heavy-chain
antibody, the variable region of the heavy-chain antibody comprises an antigenic
determinant complementary region and a skeleton region, the skeleton region is selected from the group consisting of FR1, FR2, FR3 and FR4 and
homologous sequences thereof, the antigenic
determinant complementary region is selected from the group consisting of CDR1, CDR2 and CDR3 and
homologous sequences thereof, the
amino acid sequences of the CDR1 to the CDR3 are shown in the formulas of SEQ ID NO. 1 to SEQ ID NO. 3, the
amino acid sequences of the FR1-4 are shown in formulas of SEQ ID NO. 4-7, the
amino acid sequence of the antibody is shown in the formula of SEQ ID NO.8, and the
nucleotide sequence for encoding the amino acid is shown in the formula of SEQ ID NO.9. The nano-antibody GN1 can be specifically combined with hepatoma
carcinoma cells highly expressing the GPC3
protein to inhibit hepatoma
carcinoma cell proliferation. The amino acid sequence of the nano-antibody GN1 or the nucleotidesequence of the nano-antibody GN1 or the recombinant
plasmid containing the
nucleotide sequence of the nano-antibody GN1 or the recombinant
cell containing the recombinant
plasmid containing the
nucleotide sequence of the nano-antibody GN1 can be applied to research and development of diagnostic reagents and drugs for treating
liver cancer.